about
Histocompatibility antigens, aspirin use and cognitive performance in non-demented elderly subjectsAlpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43.Aβ-dependent reduction of NCAM2-mediated synaptic adhesion contributes to synapse loss in Alzheimer's disease.C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts.Variations in the neuropathology of familial Alzheimer's disease.Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis.Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease?Inhibition of Abeta aggregation and neurotoxicity by the 39-kDa receptor-associated protein.Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes.Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease.Aneuploidy in Lewy body diseases.Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease.Role of hippocalcin in mediating Aβ toxicity.Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders.Pick bodies in a family with presenilin-1 Alzheimer's disease.Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies.Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease.Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study.Relationship between neuronal loss and 'inflammatory plaques' in early onset Alzheimer's disease.Increased aneuploidy is not a universal feature across α-synucleinopathies.Focal demyelination in Alzheimer's disease and transgenic mouse models.Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia.Inflammatory S100A9 and S100A12 proteins in Alzheimer's disease.Insoluble alpha-synuclein in Alzheimer's disease without Lewy body formation.Region- and Cell-specific Aneuploidy in Brain Aging and Neurodegeneration.TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaquesCortical Inflammation in Alzheimer Disease but Not Dementia With Lewy BodiesEffect of Anti-inflammatory Medications on Neuropathological Findings in Alzheimer DiseaseIgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple diseaseThe Neurological Consequences of Engaging in Australian Collision SportsComparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's diseaseLetter to the EditorCoexisting Lewy body disease and clinical parkinsonism in frontotemporal lobar degenerationNeuroimaging and neuropathology indices of cerebrovascular disease burden: A systematic reviewAre mutations in MAPT associated with GGT type III?Brain Banking for Research into Neurodegenerative Disorders and AgeingIntracellular and secreted forms of clusterin are elevated early in Alzheimer's disease and associate with both Aβ and tau pathologyVon Economo Neurons in Behavioral Variant Frontotemporal Dementia with Underlying Alzheimer's Disease
P50
Q28167345-0C2CF15D-687F-4BE2-A1E7-D4B8EEB5AD82Q30856480-19E24C2C-A4A9-46CC-9C4E-7AC55C1AC977Q33715607-6BC95E8D-026A-4CCD-A6C3-86BBE2B614B0Q34503220-3AB43D34-F095-427D-8EF9-3E1317FCEFF1Q36198625-AF71BE9E-2382-40A7-AA93-4059AFD81971Q37420532-38557364-A0D0-4A43-9A4C-CA77E9D0376DQ37532200-15A3992B-4CE4-4426-AAC8-160A7F1C1FEFQ38014888-18A6D6B0-BD4C-4754-8395-D43CCA08E63DQ39764826-B668F4BA-4309-4E66-8E5F-B3DD175B22D4Q40207204-47A063BB-9B83-46C1-A73A-AB41944A5A07Q40390704-987945D0-56BB-40C0-BB5D-CE1C2BF33FC2Q41572481-DAE93F7D-A4F3-4F73-834E-4D2F7D8D9E93Q43913308-76038E07-9F05-4E21-8961-3FFD7C59F1FAQ43983408-D1D0BF4C-C98C-4AC3-A687-95E9C4473681Q44342081-04CBB0AA-8576-48E4-90D5-69E67BC69069Q45204462-24B59044-B050-4AC0-A742-C2C23B248634Q45971950-DB049987-5221-4433-BEC3-3E27DBCC5C67Q46240917-E09B47F1-4510-4E9B-A35F-4E0386BE8414Q47274054-B8741519-5BF3-4AE6-A5CF-284575E698BCQ48173122-5C58CB06-7EF5-4893-8D79-9BFA16B10548Q48215747-E4AE89A3-3C4F-4AE3-84BD-A0DA03044DA7Q48285985-43722062-D0D9-4741-9F48-105723EF60C5Q48375000-BB6FDCAF-D7EA-4E83-88B8-BB2DB72B8E31Q48715457-DD84AAE5-02C8-4CED-9CB3-BCA4A2BA1575Q49160153-DA476F04-9171-41EA-BF27-DC2D8E6D4CF5Q50060875-F0190C8E-BCE2-4597-917F-8E22C73FAB89Q53366738-424D2B04-663B-49D8-942F-CC348B980488Q59544645-D02BA566-A455-47E2-9AC6-E133FA38D98EQ59544664-42DA0B94-4304-4DCB-94CB-4097E5213C21Q59544668-FF7D185B-07C9-48E7-B9A7-C921555FB721Q88698711-D1B29F18-9BC4-4736-A3AE-00DD4E8A086DQ89708461-60A214C3-FF98-4C1B-A7A7-426D1BE6000DQ90050006-2863FBC8-3455-4E91-AF1B-3526AB957DB4Q90173106-6C8A68BD-EC37-4BBF-933C-F23B1CD444E5Q90282963-DBEA91B2-6179-49EB-AF01-1F55E7656B56Q90321575-97006B02-759B-4076-8D2C-00E52156D610Q90746967-D57C6287-5A5C-47C9-A005-B41F67FA8C1DQ90859284-97D13808-681F-4417-91BA-410098BB0038Q91780753-CABE784C-139A-4FF2-BF22-D8EB5203CFEAQ92138013-A53E5096-DC37-4051-8F4E-E118A8D3AEBD
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-0399-3218
@en
name
Claire E Shepherd
@ast
Claire E Shepherd
@en
Claire E Shepherd
@es
Claire E Shepherd
@nl
type
label
Claire E Shepherd
@ast
Claire E Shepherd
@en
Claire E Shepherd
@es
Claire E Shepherd
@nl
prefLabel
Claire E Shepherd
@ast
Claire E Shepherd
@en
Claire E Shepherd
@es
Claire E Shepherd
@nl
P106
P1153
7101873981
P31
P496
0000-0002-0399-3218